Clinical Behavior and Treatment of Endometrial Cancer

被引:21
作者
Gupta, Divya [1 ]
机构
[1] Univ Connecticut, St Francis Hosp & Med Ctr, Comprehens Womens Hlth Ctr, Woodland Hosp 114, Hartford, CT 06105 USA
来源
MOLECULAR GENETICS OF ENDOMETRIAL CARCINOMA | 2017年 / 943卷
关键词
Endometrial cancer; Risk factors; Lynch syndrome; Fertility sparing; Chemotherapy; Radiation; Surgery; Minimally invasive surgery; Lymphadenectomy; PHASE-II TRIAL; PAPILLARY SEROUS CARCINOMA; WHOLE-ABDOMINAL-IRRADIATION; PACLITAXEL PLUS FILGRASTIM; CLEAR-CELL-CARCINOMA; STAGE-I; INTERMEDIATE-RISK; RADIATION-THERAPY; OVARIAN PRESERVATION; PREMENOPAUSAL WOMEN;
D O I
10.1007/978-3-319-43139-0_2
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Endometrial cancer is the most common gynecologic malignancy diagnosed in women in the developed nations. It affects a disproportionate number of reproductive-aged women. While the overall prognosis is good compared to other cancers affecting women, the pathogenesis and clinical behavior of endometrial cancer are heterogeneous. The risk factors associated with the type I and type II endometrial cancers and their pathogenesis will be discussed, as well as the evaluation and primary treatment of women with endometrial cancer. The chapter will also focus on risk stratifi cation for recurrence after surgery and role of adjuvant treatments. Finally, the treatment of recurrent endometrial cancer will be presented.
引用
收藏
页码:47 / 74
页数:28
相关论文
共 111 条
  • [1] Life-time risk of different cancers in hereditary non-polyposis colorectal cancer (HNPCC) syndrome
    Aarnio, M
    Mecklin, JP
    Aaltonen, LA
    NystromLahti, M
    Jarvinen, HJ
    [J]. INTERNATIONAL JOURNAL OF CANCER, 1995, 64 (06) : 430 - 433
  • [2] ABELER VM, 1991, GYNECOL ONCOL, V40, P207
  • [3] Use of Aromatase Inhibitors as First- and Second-Line Medical Therapy in Patients With Endometrial Adenocarcinoma: A Retrospective Study
    Altman, Alon D.
    Thompson, Jennifer
    Nelson, Gregg
    Chu, Pamela
    Nation, Jill
    Ghatage, Prafull
    [J]. JOURNAL OF OBSTETRICS AND GYNAECOLOGY CANADA, 2012, 34 (07) : 664 - 672
  • [4] Phase II trial of combination bevacizumab and temsirolimus in the treatment of A recurrent or persistent endometrial carcinoma: A Gynecologic Oncology Group study
    Alvarez, Edwin A.
    Brady, William E.
    Walker, Joan L.
    Rotmensch, Jacob
    Zhou, Xun C.
    Kendrick, James E.
    Yamada, S. Diane
    Schilder, Jeanne M.
    Cohn, David E.
    Harrison, Charles R.
    Moore, Kathleen N.
    Aghajanian, Carol
    [J]. GYNECOLOGIC ONCOLOGY, 2013, 129 (01) : 22 - 27
  • [5] American College of Obstetricians and Gynecologists, 2009, Obstet Gynecol, V113, P462, DOI 10.1097/AOG.0b013e31819930cc
  • [6] [Anonymous], 2013, Obstet Gynecol, V122, P176, DOI 10.1097/01.AOG.0000431815.52679.bb
  • [7] [Anonymous], 2015, NATL CANC COMPREHENS
  • [8] Does immediate hormone replacement therapy affect the oncologic outcome in endometrial cancer survivors?
    Ayhan, A
    Taskiran, C
    Simseky, S
    Severy, A
    [J]. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2006, 16 (02) : 805 - 808
  • [9] Randomized double-blind trial of estrogen replacement therapy versus placebo in stage I or II endometrial cancer: A Gynecologic Oncology Group Study
    Barakat, RR
    Bundy, BN
    Spirtos, NM
    Bell, J
    Mannel, RS
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (04) : 587 - 592
  • [10] Pelvic exenteration for recurrent endometrial cancer
    Barakat, RR
    Goldman, NA
    Patel, DA
    Venkatraman, ES
    Curtin, JP
    [J]. GYNECOLOGIC ONCOLOGY, 1999, 75 (01) : 99 - 102